Monday, April 04, 2022 9:29:45 AM
"We figured we could make at least 12,000 or 13,000 treatments a year. And we looked at it in terms of dollars, that's close to two billion dollars. Guys, we have the existing facility. So what we have is we have created a drug, the likes of which never the world has never seen. It should become part of the standard of care, one of the two arms of head and neck cancer. That's 210,000 people. No safety issues. It's a big deal. We've done a ten year study, that’s the largest ever in head and neck cancer, one of the biggest cancers in the world. We're the first in the world to show benefit from using a cancer drug before surgery and radiation. We built our manufacturing facility before phase 3 and doubled its capacity over the past year."
"It is becoming clear to me that there are financial reasons for others that just don't want us to succeed. The concept of a new, non-toxic cancer drug is something no one has done before. We believe it's all about helping people, and we believe that the FDA will see it the same way."
https://biotechhealthx.com/biotech-ceo-interviews/exclusive-cel-sci-ceo-geert-kersten-talks-multikine-fda-approval-cvm-future/
Tick tock, tick tock...
Recent CVM News
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 10/08/2024 09:13:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/01/2024 01:13:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/01/2024 01:05:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/01/2024 12:58:09 PM
- CEL-SCI Selects Ergomed as CRO as it Gears Up for Confirmatory FDA Registration Study of Multikine® in Head and Neck Cancer • Business Wire • 10/01/2024 10:00:00 AM
- CEL-SCI’s Multikine® Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and Radiation • Business Wire • 09/16/2024 11:30:00 AM
- CEL-SCI to Present New Data for Multikine® Head & Neck Cancer Immunotherapy at the European Society for Medical Oncology 2024 Congress • Business Wire • 09/10/2024 01:32:00 PM
- The UK’s Medicines & Healthcare Products Regulatory Agency Grants CEL-SCI a Pediatric Waiver, Bringing Multikine® One Step Closer to Future Marketing Clearance • Business Wire • 09/04/2024 01:00:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 08/30/2024 08:32:13 PM
- CEL-SCI Corporation Reports Third Quarter Fiscal 2024 Financial Results • Business Wire • 08/15/2024 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 08:27:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/29/2024 09:16:11 PM
- CEL-SCI Announces Closing of $10.8 Million Offering • Business Wire • 07/29/2024 08:05:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/29/2024 11:00:58 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/26/2024 09:27:40 PM
- CEL-SCI Announces Pricing of $10.8 Million Offering • Business Wire • 07/26/2024 03:52:00 PM
- CEL-SCI’s Phase 3 Population Analysis for Upcoming Confirmatory Registration Study in Head & Neck Cancer Demonstrates Well Balanced Patient Population, Confidence in Clinical Results • Business Wire • 07/26/2024 12:23:00 PM
- CEL-SCI Appoints Robert Watson as Chairperson of the Board • Business Wire • 07/08/2024 01:15:00 PM
- CEL-SCI Presents Head & Neck Cancer Data at Iddst Annual Congress in Budapest: Risk of Death Cut in Half for Patients Treated With Multikine in the Target Population • Business Wire • 06/18/2024 12:00:00 PM
- Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor • Business Wire • 06/06/2024 11:00:00 AM
- CEL-SCI Corporation Reports Second Quarter Fiscal 2024 Financial Results • Business Wire • 05/16/2024 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2024 08:17:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/10/2024 01:04:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/09/2024 05:07:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/09/2024 01:19:04 PM
FEATURED CBD Life Sciences, Inc. (CBDL) Reaches Unprecedented Heights With Explosive Growth and Strategic Expansion in 2024 • Oct 8, 2024 8:00 AM
BNCM COMPLETES MERGER WITH DELEX HEALTHCARE • BNCM • Oct 8, 2024 9:54 AM
Unitronix Corp. to Invest $3 Million in USA Unity Coin Project • UTRX • Oct 7, 2024 7:08 AM
North Bay Resources Announces Assays up to 5 oz/ton Gold, 1.5 oz/ton Platinum, 0.5 oz/ton Palladium, and 0.5 oz/ton Rhodium at Mt. Vernon Gold Mine, Sierra County, California • NBRI • Oct 4, 2024 9:15 AM
Basanite, Inc. Appoints Ali Manav as Interim Chief Executive Officer • BASA • Oct 3, 2024 9:15 AM
Integrated Ventures Announces Launch of MedWell Facilities, LLC and Lease Agreement with Giant Fitness Clubs • INTV • Oct 3, 2024 8:45 AM